Mohamed Altai
Mohamed Altai
Verified email at bms.uu.se
Title
Cited by
Cited by
Year
Pretargeted imaging and therapy
M Altai, R Membreno, B Cook, V Tolmachev, BM Zeglis
Journal of Nuclear Medicine 58 (10), 1553-1559, 2017
862017
Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties
H Wållberg, A Orlova, M Altai, SJ Hosseinimehr, C Widström, J Malmberg, ...
Journal of Nuclear Medicine 52 (3), 461-469, 2011
822011
HAHAHA, HEHEHE, HIHIHI, or HKHKHK: Influence of Position and Composition of Histidine Containing Tags on Biodistribution of [99mTc(CO)3]+-Labeled …
C Hofström, M Altai, H Honarvar, J Strand, J Malmberg, ...
Journal of medicinal chemistry 56 (12), 4966-4974, 2013
592013
Use of a HEHEHE purification tag instead of a hexahistidine tag improves biodistribution of affibody molecules site-specifically labeled with 99mTc, 111In, and 125I
C Hofström, A Orlova, M Altai, F Wångsell, T Gräslund, V Tolmachev
Journal of medicinal chemistry 54 (11), 3817-3826, 2011
572011
The effect of mini-PEG-based spacer length on binding and pharmacokinetic properties of a 68Ga-labeled NOTA-conjugated antagonistic analog of bombesin
Z Varasteh, U Rosenström, I Velikyan, B Mitran, M Altai, H Honarvar, ...
Molecules 19 (7), 10455-10472, 2014
562014
Feasibility of affibody molecule-based PNA-mediated radionuclide pretargeting of malignant tumors
H Honarvar, K Westerlund, M Altai, M Sandström, A Orlova, V Tolmachev, ...
Theranostics 6 (1), 93, 2016
532016
Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111 In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing …
J Malmberg, A Perols, Z Varasteh, M Altai, A Braun, M Sandström, ...
European journal of nuclear medicine and molecular imaging 39 (3), 481-492, 2012
502012
Imaging of HER3-expressing xenografts in mice using a 99m Tc (CO) 3-HEHEHE-Z HER3: 08699 affibody molecule
A Orlova, M Malm, M Rosestedt, Z Varasteh, K Andersson, RK Selvaraju, ...
European journal of nuclear medicine and molecular imaging 41 (7), 1450-1459, 2014
482014
Feasibility of affibody-based bioorthogonal chemistry–mediated radionuclide pretargeting
M Altai, A Perols, M Tsourma, B Mitran, H Honarvar, M Robillard, ...
Journal of Nuclear Medicine 57 (3), 431-436, 2016
462016
Influence of Nuclides and Chelators on Imaging Using Affibody Molecules: Comparative Evaluation of Recombinant Affibody Molecules Site-Specifically Labeled with 68Ga …
M Altai, J Strand, D Rosik, RK Selvaraju, A Eriksson Karlström, A Orlova, ...
Bioconjugate chemistry 24 (6), 1102-1109, 2013
442013
Comparative evaluation of radioiodine and technetium-labeled DARPin 9_29 for radionuclide molecular imaging of HER2 expression in malignant tumors
A Vorobyeva, O Bragina, M Altai, B Mitran, A Orlova, A Shulga, ...
Contrast media & molecular imaging 2018, 2018
372018
In vivo and in vitro studies on renal uptake of radiolabeled affibody molecules for imaging of HER2 expression in tumors
M Altai, Z Varasteh, K Andersson, A Eek, O Boerman, A Orlova
Cancer Biotherapy and Radiopharmaceuticals 28 (3), 187-195, 2013
352013
Evaluation of a maleimido derivative of NOTA for site-specific labeling of affibody molecules
V Tolmachev, M Altai, M Sandström, A Perols, AE Karlström, ...
Bioconjugate chemistry 22 (5), 894-902, 2011
352011
Radionuclide tumor targeting using ADAPT scaffold proteins: aspects of label positioning and residualizing properties of the label
S Lindbo, J Garousi, B Mitran, M Altai, J Buijs, A Orlova, S Hober, ...
Journal of Nuclear Medicine 59 (1), 93-99, 2018
342018
Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors
M Altai, H Liu, H Ding, B Mitran, PH Edqvist, V Tolmachev, A Orlova, ...
Journal of Controlled Release 288, 84-95, 2018
322018
Radionuclide therapy of HER2-expressing human xenografts using affibody-based peptide nucleic acid–mediated pretargeting: in vivo proof of principle
K Westerlund, M Altai, B Mitran, M Konijnenberg, M Oroujeni, C Atterby, ...
Journal of Nuclear Medicine 59 (7), 1092-1098, 2018
322018
Incorporation of a Triglutamyl Spacer Improves the Biodistribution of Synthetic Affibody Molecules Radiofluorinated at the N-Terminus via Oxime Formation with 18F …
D Rosik, A Thibblin, G Antoni, H Honarvar, J Strand, RK Selvaraju, M Altai, ...
Bioconjugate chemistry 25 (1), 82-92, 2014
292014
Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99m Tc-labelling at the C terminus
H Lindberg, C Hofström, M Altai, H Honorvar, H Wållberg, A Orlova, ...
Tumor Biology 33 (3), 641-651, 2012
242012
Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA
M Altai, A Perols, AE Karlström, M Sandström, F Boschetti, A Orlova, ...
Nuclear medicine and biology 39 (4), 518-529, 2012
242012
Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99m Tc-labeled recombinant Affibody molecules
M Altai, H Wållberg, A Orlova, M Rosestedt, SJ Hosseinimehr, ...
Amino acids 42 (5), 1975-1985, 2012
242012
The system can't perform the operation now. Try again later.
Articles 1–20